The Native Antigen Company has launched its SARS-CoV-2 Neutralisation Assay Development Kit, which can be used to identify and qualitatively assess the ability of antibodies to neutralise SARS-CoV-2-receptor binding.
The easy-to-use kit, which will support research into variants and their effects on natural and vaccine-induced patient immunity, contains all the key reagents required to measure SARS-CoV-2-antibody binding, including the spike receptor-binding domain (RBD) of the prototypic Wuhan-Hu-1 strain, labelled ACE2, and positive and negative monoclonal antibody controls.
These reagents enable the assessment of neutralising activity of patient and therapeutic antibodies, and can be used alongside The Native Antigen Company’s growing range of SARS-CoV-2 variant spike proteins to assess differences in antibody/ACE2 affinities and competitive binding.
Dr Andy Lane (Commercial Director, The Native Antigen Company) said: “This marks The Native Antigen Company’s first release of a dedicated kit for the development of neutralisation assays. Our data demonstrate the SARS-CoV-2 Neutralisation Assay Development Kit’s effectiveness and we are confident in its ability to support vital research and development efforts for public health.”
The Native Antigen Company’s in-house data show that COVID-19 patient sera is able to neutralise the RBD effectively and prevent it from binding to the human ACE2 cell-surface receptor.
Further information about The Native Antigen Company’s SARS-CoV-2 Neutralisation Assay Development Kit is available here.
